Comparative Pharmacology
Head-to-head clinical analysis: ANSAID versus INDOMETHACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSAID versus INDOMETHACIN.
ANSAID vs INDOMETHACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
25-50 mg orally 2-3 times daily; maximum 200 mg/day. Also available as 75 mg sustained-release capsule orally once daily, or 50 mg rectally 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged.
Clinical Note
moderateIndomethacin + Gatifloxacin
"Indomethacin may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateIndomethacin + Rosoxacin
"Indomethacin may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateIndomethacin + Levofloxacin
"Indomethacin may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateIndomethacin + Trovafloxacin
Terminal elimination half-life is approximately 4.5 hours (range 2.6-11.2 hours) in adults; prolonged in neonates (up to 17 hours) and in patients with renal impairment or cholestasis; clinical context: dosing interval adjustments needed in hepatic or renal disease.
Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts.
Renal excretion of unchanged drug and metabolites (approximately 60% as parent drug and glucuronide conjugate; 23% as O-desmethyl metabolite; 13% as glucuronide of O-desmethyl metabolite); biliary/fecal elimination accounts for 30-40%, primarily as glucuronide conjugates.
Category C
Category D/X
NSAID
NSAID
"Indomethacin may increase the neuroexcitatory activities of Trovafloxacin."